Member-only story
Merck acquires Acceleron Pharma for $11.5B to expand the cardiovascular pipeline
To aid the growth of its expanding cardiovascular treatments pipeline, Merck is striking an acquisition deal worth $11.5B with Acceleron Pharma. It is a Massachusetts-based clinical-stage biopharmaceutical company that focuses on developing protein-based therapeutics to grow and repair cells and tissues in order to treat cancers and other rare diseases. The U.S.-based multinational biopharmaceutical company is looking to acquire more companies for further opportunities.
The giant pharma group has bought Acceleron’s shares for $180 per share in terms of cash and the closing of the deal is anticipated in the fourth quarter.
The acquisition deal is the most recent one among the emerging pharma companies being acquired by large pharma groups to boost their revenues.
Acceleron is marketing its Reblozyl therapy in the U.S., Canada, and Europe for treating anemia in certain blood disorders. The drug is being marketed in collaboration with Bristol Myers Squibb which has 11.5% shares in the emerging company.
According to the CEO, Rob Davis, the deal would give Merck the rights of Sotatercept, which is the potential blockbuster drug candidate for treating a rare high blood pressure disorder and is currently in phase III trials. The company is…
